237 related articles for article (PubMed ID: 36397165)
21. Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis.
Kodama T; Yi J; Newberg JY; Tien JC; Wu H; Finegold MJ; Kodama M; Wei Z; Tamura T; Takehara T; Johnson RL; Jenkins NA; Copeland NG
Proc Natl Acad Sci U S A; 2018 Oct; 115(44):E10417-E10426. PubMed ID: 30327349
[TBL] [Abstract][Full Text] [Related]
22. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis: HCC and Steatosis or Steatohepatitis.
Petrelli F; Manara M; Colombo S; De Santi G; Ghidini M; Mariani M; Iaculli A; Rausa E; Rampulla V; Arru M; Viti M; Lonati V; Ghidini A; Luciani A; Facciorusso A
Neoplasia; 2022 Aug; 30():100809. PubMed ID: 35636146
[TBL] [Abstract][Full Text] [Related]
23. Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors.
Dongiovanni P; Romeo S; Valenti L
World J Gastroenterol; 2014 Sep; 20(36):12945-55. PubMed ID: 25278690
[TBL] [Abstract][Full Text] [Related]
24. A micro-RNA expression signature for human NAFLD progression.
Guo Y; Xiong Y; Sheng Q; Zhao S; Wattacheril J; Flynn CR
J Gastroenterol; 2016 Oct; 51(10):1022-30. PubMed ID: 26874844
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of aberrantly expressed methylation genes in human hepatocellular carcinoma.
Zhen L; Ning G; Wu L; Zheng Y; Yang F; Chen T; Xu W; Liu Y; Xie C; Peng L
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32955083
[TBL] [Abstract][Full Text] [Related]
26. Cellular and molecular alterations in a human hepatocellular in vitro model of nonalcoholic fatty liver disease development and stratification.
Willett RA; Tryndyak VP; Beland FA; Pogribny IP
J Environ Sci Health C Toxicol Carcinog; 2024; 42(1):74-92. PubMed ID: 38105681
[TBL] [Abstract][Full Text] [Related]
27. Unique features associated with hepatic oxidative DNA damage and DNA methylation in non-alcoholic fatty liver disease.
Nishida N; Yada N; Hagiwara S; Sakurai T; Kitano M; Kudo M
J Gastroenterol Hepatol; 2016 Sep; 31(9):1646-53. PubMed ID: 26875698
[TBL] [Abstract][Full Text] [Related]
28. Identification of differentially methylated regions associated with both liver fibrosis and hepatocellular carcinoma.
Kurokawa S; Kobori T; Yoneda M; Ogawa Y; Honda Y; Kessoku T; Imajo K; Saito S; Nakajima A; Hotta K
BMC Gastroenterol; 2024 Feb; 24(1):57. PubMed ID: 38302914
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
[TBL] [Abstract][Full Text] [Related]
30. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma.
Ki Kim S; Ueda Y; Hatano E; Kakiuchi N; Takeda H; Goto T; Shimizu T; Yoshida K; Ikura Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Uemoto S; Chiba T; Ogawa S; Marusawa H
Int J Cancer; 2016 Dec; 139(11):2512-8. PubMed ID: 27511114
[TBL] [Abstract][Full Text] [Related]
31. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis.
Bengtsson B; Stål P; Wahlin S; Björkström NK; Hagström H
Liver Int; 2019 Jun; 39(6):1098-1108. PubMed ID: 30829446
[TBL] [Abstract][Full Text] [Related]
32. Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
Pelusi S; Baselli G; Pietrelli A; Dongiovanni P; Donati B; McCain MV; Meroni M; Fracanzani AL; Romagnoli R; Petta S; Grieco A; Miele L; Soardo G; Bugianesi E; Fargion S; Aghemo A; D'Ambrosio R; Xing C; Romeo S; De Francesco R; Reeves HL; Valenti LVC
Sci Rep; 2019 Mar; 9(1):3682. PubMed ID: 30842500
[TBL] [Abstract][Full Text] [Related]
33. Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease.
Than NN; Ghazanfar A; Hodson J; Tehami N; Coldham C; Mergental H; Manas D; Shah T; Newsome PN; Reeves H; Shetty S
QJM; 2017 Feb; 110(2):73-81. PubMed ID: 27634970
[TBL] [Abstract][Full Text] [Related]
34. Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
Chan TT; Chan WK; Wong GL; Chan AW; Nik Mustapha NR; Chan SL; Chong CC; Mahadeva S; Shu SS; Lai PB; Chan HL; Wong VW
Am J Gastroenterol; 2020 Jun; 115(6):867-875. PubMed ID: 32149781
[TBL] [Abstract][Full Text] [Related]
35. Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System.
Kikuchi L; Oliveira CP; Alvares-da-Silva MR; Tani CM; Diniz MA; Stefano JT; Chagas AL; Alencar RS; Vezozzo DC; Santos GR; Campos PB; Alves VA; Ratziu V; Carrilho FJ
Am J Clin Oncol; 2016 Oct; 39(5):428-32. PubMed ID: 25268068
[TBL] [Abstract][Full Text] [Related]
36. Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with increasing DNA promoter methylation.
Zekri Ael-R; Nassar AA; El-Din El-Rouby MN; Shousha HI; Barakat AB; El-Desouky ED; Zayed NA; Ahmed OS; El-Din Youssef AS; Kaseb AO; Abd El-Aziz AO; Bahnassy AA
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6721-6. PubMed ID: 24377595
[TBL] [Abstract][Full Text] [Related]
37. Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan.
Akuta N; Kawamura Y; Suzuki F; Saitoh S; Arase Y; Kunimoto H; Sorin Y; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Kobayashi M; Ikeda K; Kumada H
Hepatol Int; 2016 Jul; 10(4):647-56. PubMed ID: 27074850
[TBL] [Abstract][Full Text] [Related]
38. Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease.
Ponziani FR; Bhoori S; Castelli C; Putignani L; Rivoltini L; Del Chierico F; Sanguinetti M; Morelli D; Paroni Sterbini F; Petito V; Reddel S; Calvani R; Camisaschi C; Picca A; Tuccitto A; Gasbarrini A; Pompili M; Mazzaferro V
Hepatology; 2019 Jan; 69(1):107-120. PubMed ID: 29665135
[TBL] [Abstract][Full Text] [Related]
39. Should Patients With NAFLD/NASH Be Surveyed for HCC?
Reig M; Gambato M; Man NK; Roberts JP; Victor D; Orci LA; Toso C
Transplantation; 2019 Jan; 103(1):39-44. PubMed ID: 30080818
[TBL] [Abstract][Full Text] [Related]
40. Identification of differentially methylated region (DMR) networks associated with progression of nonalcoholic fatty liver disease.
Hotta K; Kitamoto A; Kitamoto T; Ogawa Y; Honda Y; Kessoku T; Yoneda M; Imajo K; Tomeno W; Saito S; Nakajima A
Sci Rep; 2018 Sep; 8(1):13567. PubMed ID: 30206277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
